ONCOLOGY PRECISION MEDICINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Oncology Precision Medicine Market, By Component (Therapeutics (Targeted therapies, Targeted biologics, Precision immuno-oncology, Cell & gene therapies, Radiotheranostics / targeted radionuclide therapies, Combination regimens), Diagnostics / Testing (Companion diagnostics (CDx), Complementary diagnostics, Comprehensive genomic profiling (CGP) panels, Minimal residual disease (MRD) testing, and Pharmacogenomics (PGx) relevant to oncology regimens), Informatics & Decision Support (Clinical decision support (CDS) / treatment matching engines, Variant interpretation & annotation platforms, Molecular tumor board (MTB) enablement software, and Data integration (EHR/LIS/omics) & interoperability tools, and Services (Sample logistics, biobanking, and pre-analytics services, Bioinformatics services (pipeline, interpretation, reporting), Clinical trial matching services, Real-world evidence (RWE) and outcomes analytics, and Contract research / companion diagnostic development services)), , By Care Pathway Stage (Risk Assessment & Screening, Diagnosis & Tumor Classification, Therapy Selection, Treatment Monitoring (Response Monitoring, Resistance Emergence Detection, Dose/Therapy Optimization), Recurrence Surveillance / MRD, and Clinical Trial Enrolment & Matching), By Technology (Genomics (Next-generation sequencing (NGS) (Targeted panels, Whole exome sequencing (WES), and Whole genome sequencing (WGS)), PCR / qPCR / ddPCR, Sanger sequencing (confirmatory)), Transcriptomics (RNA sequencing (RNA-seq), Gene expression profiling / signatures), Proteomics / Protein biomarkers, (Immunohistochemistry (IHC), Mass spectrometry–based proteomics (select settings)), Cytogenetics & Structural Variation (FISH, Karyotyping (certain hematologic cancers), Epigenetics (DNA methylation profiling (select tumors), Liquid biopsy technologies (ctDNA / cfDNA, CTCs, Exosomes / extracellular vesicles (emerging)), Single-cell & spatial, (Single-cell sequencing (scRNA/scDNA), Spatial transcriptomics / multiplex imaging)), By Biomarker Type (Genetic biomarkers (Single nucleotide variants (SNVs), Indels, Copy number variations (CNVs), Gene fusions / rearrangements, Germline variants (hereditary cancer)), Genomic signatures / global markers, Tumor mutational burden (TMB), Microsatellite instability (MSI), Homologous recombination deficiency (HRD)), Expression / protein markers, (Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)), Epigenetic biomarkers, (Methylation signatures), MRD biomarkers, (Personalized tumor-informed MRD, Tumor-naïve MRD panels)), By Sample Type (Tissue-based (FFPE tissue, Fresh frozen tissue, Core needle biopsy / surgical specimens), Blood-based (liquid biopsy) (Plasma (ctDNA/cfDNA), Whole blood (CTCs, RNA), Other biofluids (Urine, saliva, CSF (indication-dependent)), Cytology samples (FNA, smears (select workflows)), By End User (Hospitals & cancer centers, Diagnostic laboratories (Clinical pathology labs, Molecular/genetic labs), Academic & research institutes, Pharmaceutical & biotech companies, CROs / clinical trial networks, and Payers / HTA bodies), By Cancer Type (Solid Tumors, Hematologic Malignancies, and Rare Cancers / Tumor-agnostic Segments (Tumor-agnostic biomarker-defined populations)), By Reimbursement & Access Channel (Public Reimbursement, Private Reimbursement, Out-of-pocket / Self-pay, Hybrid coverage models, Patient Assistance / Access Programs, and Clinical trial–funded Testing), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

Published In: 09 Feb, 2026
Code: CMI9316
Page number: 152
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026-2033

According to Coherent Market Insights, the global oncology precision medicine market is estimated to be valued at USD 190.50 Bn in 2026 and is expected to reach USD 366.53 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033. The global oncology precision medicine market represents a revolutionary paradigm shift in cancer treatment, fundamentally transforming how healthcare providers approach diagnosis, treatment selection, and patient care management. Precision medicine in oncology leverages advanced genomic sequencing, biomarker identification, molecular diagnostics, and artificial intelligence to deliver highly personalized therapeutic interventions tailored to individual patient profiles and specific tumor characteristics.

This innovative approach moves beyond the traditional one-size-fits-all treatment methodology, enabling clinicians to identify optimal therapeutic pathways based on genetic mutations, protein expressions, and cellular pathways unique to each patient's malignancy. The integration of cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsies, pharmacogenomics, and companion diagnostics has accelerated the development of targeted therapies, immunotherapies, and combination treatment protocols that demonstrate superior efficacy rates and reduced adverse effects. As healthcare systems worldwide increasingly adopt value-based care models and seek to improve patient outcomes while managing costs, precision medicine emerges as a critical solution that promises to enhance treatment response rates, minimize trial-and-error prescribing, and ultimately improve survival rates across various cancer types including lung, breast, colorectal, melanoma, and hematological malignancies.

Market Dynamics

The global oncology precision medicine market is propelled by several compelling drivers that continue to accelerate market expansion and adoption rates across healthcare institutions worldwide. The primary growth driver stems from the rapidly declining costs of genomic sequencing technologies, making precision diagnostics more accessible and economically viable for routine clinical implementation, while simultaneously increasing cancer incidence rates globally create an urgent demand for more effective, personalized treatment solutions.

Technological advancements in artificial intelligence, machine learning algorithms, and big data analytics enable healthcare providers to process vast amounts of genomic and clinical data, facilitating more accurate treatment predictions and drug selection processes. Government initiatives, regulatory support, and substantial investments in precision medicine research from both public and private sectors further accelerate market growth, with organizations like the U.S. FDA streamlining approval processes for companion diagnostics and targeted therapies.

However, the market faces significant restraints including high implementation costs for healthcare facilities, particularly in developing regions, complex regulatory frameworks that vary across different countries, and the need for specialized infrastructure and trained personnel to effectively utilize precision medicine technologies. Data privacy concerns, ethical considerations surrounding genetic testing, and limited reimbursement policies in certain healthcare systems also impede market penetration.

Nevertheless, substantial opportunities emerge from expanding applications in rare cancers, growing adoption of liquid biopsy technologies, increasing pharmaceutical partnerships for biomarker-driven drug development, and the potential for precision medicine integration into routine clinical workflows, particularly as healthcare digitization accelerates and personalized treatment becomes the standard of care across oncology practices globally.

Key Features of the Study

This report provides in-depth analysis of the global oncology precision medicine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global oncology precision medicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F. Hoffmann‑La Roche Ltd, Novartis AG, Pfizer Inc, AstraZeneca plc, Bristol‑Myers Squibb Company, Merck & Co Inc, Gilead Sciences Inc, Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN NV, BioNTech SE, Amgen Inc, Foundation Medicine Inc, Guardant Health, and Myriad Genetics Inc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global oncology precision medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology precision medicine market

Market Segmentation

Component Insights (Revenue, USD Bn, 2021 - 2033)
- Therapeutics
  - Targeted therapies
  - Targeted biologics
  - Precision immuno-oncology
  - Cell & gene therapies
  - Radiotheranostics / targeted radionuclide therapies
  - Combination regimens
- Diagnostics / Testing
  - Companion diagnostics (CDx)
  - Complementary diagnostics
  - Comprehensive genomic profiling (CGP) panels
  - Minimal residual disease (MRD) testing
  - Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
  - Clinical decision support (CDS) / treatment matching engines
  - Variant interpretation & annotation platforms
  - Molecular tumor board (MTB) enablement software
  - Data integration (EHR/LIS/omics) & interoperability tools
- Services
  - Sample logistics, biobanking, and pre-analytics services
  - Bioinformatics services (pipeline, interpretation, reporting)
  - Clinical trial matching services
  - Real-world evidence (RWE) and outcomes analytics
  - Contract research / companion diagnostic development services
Care Pathway Stage (Revenue, USD Bn, 2021 - 2033)
- Risk assessment & screening
- Diagnosis & tumor classification
- Therapy selection
- Treatment monitoring
  - Response monitoring
  - Resistance emergence detection
  - Dose/therapy optimization
- Recurrence surveillance / MRD
- Clinical trial enrolment & matching
Technology (Revenue, USD Bn, 2021 - 2033)
- Genomics
  - Next-generation sequencing (NGS)
    - Targeted panels
    - Whole exome sequencing (WES)
    - Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
  - RNA sequencing (RNA-seq)
  - Gene expression profiling / signatures
- Proteomics / Protein biomarkers
  - Immunohistochemistry (IHC)
  - Mass spectrometry–based proteomics (select settings)
- Cytogenetics & Structural Variation
  - FISH
  - Karyotyping (certain hematologic cancers)
- Epigenetics
  - DNA methylation profiling (select tumors)
- Liquid biopsy technologies
  - ctDNA / cfDNA
  - CTCs
  - Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
  - Single-cell sequencing (scRNA/scDNA)
  - Spatial transcriptomics / multiplex imaging
Biomarker Type (Revenue, USD Bn, 2021 - 2033)
- Genetic biomarkers
  - Single nucleotide variants (SNVs)
  - Indels
  - Copy number variations (CNVs)
  - Gene fusions / rearrangements
  - Germline variants (hereditary cancer)
- Genomic signatures / global markers
  - Tumor mutational burden (TMB)
  - Microsatellite instability (MSI)
  - Homologous recombination deficiency (HRD)
- Expression / protein markers
  - Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic biomarkers
  - Methylation signatures
- MRD biomarkers
  - Personalized tumor-informed MRD
  - Tumor-naïve MRD panels
Sample Type (Revenue, USD Bn, 2021 - 2033)
- Tissue-based
  - FFPE tissue
  - Fresh frozen tissue
  - Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
  - Plasma (ctDNA/cfDNA)
  - Whole blood (CTCs, RNA)
- Other biofluids
  - Urine, saliva, CSF (indication-dependent)
- Cytology samples
  - FNA, smears (select workflows)
End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals & cancer centers
- Diagnostic laboratories
  - Clinical pathology labs
  - Molecular/genetic labs
- Academic & research institutes
- Pharmaceutical & biotech companies
- CROs / clinical trial networks
- Payers / HTA bodies
Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Solid tumors
  - Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic malignancies
  - Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare cancers / tumor-agnostic segments
  - Tumor-agnostic biomarker-defined populations
Reimbursement & Access Channel (Revenue, USD Bn, 2021 - 2033)
- Public reimbursement
- Private reimbursement
- Out-of-pocket / self-pay
- Hybrid coverage models
- Patient assistance / access programs
- Clinical trial–funded testing
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Hoffmann‑La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol‑Myers Squibb Company
- Merck & Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Oncology Precision Medicine Market, By Component
  - Global Oncology Precision Medicine Market, By Care Pathway Stage
  - Global Oncology Precision Medicine Market, By Technology
  - Global Oncology Precision Medicine Market, By Biomarker Type
  - Global Oncology Precision Medicine Market, By Sample Type
  - Global Oncology Precision Medicine Market, By End User
  - Global Oncology Precision Medicine Market, By Cancer Type
  - Global Oncology Precision Medicine Market, By Reimbursement & Access Channel
  - Global Oncology Precision Medicine Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
Global Oncology Precision Medicine Market, By Component, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Therapeutics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Targeted therapies
    - Targeted biologics
    - Precision immuno-oncology
    - Cell & gene therapies
    - Radiotheranostics / targeted radionuclide therapies
    - Combination regimens
- Diagnostics / Testing
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Companion diagnostics (CDx)
    - Complementary diagnostics
    - Comprehensive genomic profiling (CGP) panels
    - Minimal residual disease (MRD) testing
    - Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Clinical decision support (CDS) / treatment matching engines
    - Variant interpretation & annotation platforms
    - Molecular tumor board (MTB) enablement software
    - Data integration (EHR/LIS/omics) & interoperability tools
- Services
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Sample logistics, biobanking, and pre-analytics services
    - Bioinformatics services (pipeline, interpretation, reporting)
    - Clinical trial matching services
    - Real-world evidence (RWE) and outcomes analytics
    - Contract research / companion diagnostic development services
Global Oncology Precision Medicine Market, By Care Pathway Stage, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Risk Assessment & Screening
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnosis & Tumor Classification
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Therapy Selection
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Treatment Monitoring
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Response Monitoring
    - Resistance Emergence Detection
    - Dose/Therapy Optimization
- Recurrence Surveillance / MRD
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical Trial Enrolment & Matching
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Oncology Precision Medicine Market, By Technology, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Genomics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  - Next-generation sequencing (NGS)
    - Targeted panels
    - Whole exome sequencing (WES)
    - Whole genome sequencing (WGS)
  - PCR / qPCR / ddPCR
  - Sanger sequencing (confirmatory)
- Transcriptomics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - RNA sequencing (RNA-seq)
    - Gene expression profiling / signatures
- Proteomics / Protein biomarkers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Immunohistochemistry (IHC)
    - Mass spectrometry–based proteomics (select settings)
- Cytogenetics & Structural Variation
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - FISH
    - Karyotyping (certain hematologic cancers)
- Epigenetics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - DNA methylation profiling (select tumors)
- Liquid biopsy technologies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - ctDNA / cfDNA
    - CTCs
    - Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Single-cell sequencing (scRNA/scDNA)
    - Spatial transcriptomics / multiplex imaging
Global Oncology Precision Medicine Market, By Biomarker Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Genetic Biomarkers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Single nucleotide variants (SNVs)
    - Indels
    - Copy number variations (CNVs)
    - Gene fusions / rearrangements
    - Germline variants (hereditary cancer)
- Genomic Signatures / Global Markers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Tumor mutational burden (TMB)
    - Microsatellite instability (MSI)
    - Homologous recombination deficiency (HRD)
- Expression / Protein Markers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic Biomarkers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Methylation signatures
- MRD Biomarkers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Personalized tumor-informed MRD
    - Tumor-naïve MRD panels
Global Oncology Precision Medicine Market, By Sample Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Tissue-based
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - FFPE tissue
    - Fresh frozen tissue
    - Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Plasma (ctDNA/cfDNA)
    - Whole blood (CTCs, RNA)
- Other Biofluids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Urine, saliva, CSF (indication-dependent)
- Cytology Samples
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - FNA, Smears (Select Workflows)
Global Oncology Precision Medicine Market, By End User, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Hospitals & cancer centers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic laboratories
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Clinical pathology labs
    - Molecular/genetic labs
- Academic & research institutes
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical & biotech companies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CROs / clinical trial networks
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Payers / HTA bodies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Oncology Precision Medicine Market, By Cancer Type, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Solid Tumors
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic Malignancies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare Cancers / Tumor-agnostic Segments
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    - Tumor-agnostic biomarker-defined populations
Global Oncology Precision Medicine Market, By Reimbursement & Access Channel, 2021-2033, (USD Bn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Public Reimbursement
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Private Reimbursement
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Out-of-pocket / Self-pay
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hybrid coverage models
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Patient Assistance / Access Programs
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical trial–funded Testing
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Global Oncology Precision Medicine Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
  - Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Hoffmann‑La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AstraZeneca plc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bristol‑Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Gilead Sciences Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Illumina Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Thermo Fisher Scientific Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- QIAGEN NV
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- BioNTech SE
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Amgen Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Foundation Medicine Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Guardant Health
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Myriad Genetics Inc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on 'Oncology Precision Medicine Market' - Global forecast to 2033

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now